Compare UiPath Inc (PATH) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Zimmer Biomet Holdings Inc — how do they compare? UiPath Inc trades at $10.64 (market cap $6.24B), while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.8× UiPath Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| PATH | ZBH | |
|---|---|---|
Market Cap | $6.24B | $17.20B |
Sector | Technology | Health |
52-Week High | $19.29 | $107.71 |
52-Week Low | $9.38 | $79.58 |
Enterprise Value | $5.01B | $24.25B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $12.04, down 0.91% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while narrowing net losses signal a path toward sustained profitability. Recent news highlights strong annual recurring revenue growth to $1.9B and strategic AI automation developments through its Maestro platform.
The investment outlook is cautiously optimistic, supported by analyst consensus and improving margins, but risks include competitive pressures in AI automation and volatility in software spending. The stock presents a potential opportunity if execution on profitability continues, though near-term earnings misses warrant monitoring.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
